PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
UnitedHealthcareMedicaid · Coverage · Medical Policy · TN · Oncology, Radiation Oncology, Radiology +1 moreMedium impact

Transarterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT) for the Treatment of Malignant Cancers of the Liver (for Tennessee Only)

Effective date
Dec 1, 2026
Identified
Nov 7, 2026

Summary

Effective 2026-12-01, UnitedHealthcare Community Plan of Tennessee revised its Medicaid medical policy for transarterial radioembolization (TARE)/selective internal radiation therapy (SIRT) using yttrium-90 microspheres for liver malignancies, applicable to Tennessee members 19 years of age or older. The proven and medically necessary indications for patients with ECOG status 0, 1, or 2 were updated, most notably changing the uveal melanoma indication to read "metastasis from uveal melanoma when confined to the liver" (previously "uveal/ocular melanoma"), and the TARE definition was updated; all other indications are considered unproven and not medically necessary.

Get alerts when payers change rules like this one

We check UnitedHealthcare and other payers every day and email you when a change matches your specialty and state.

Get UnitedHealthcare alertsPolicy Monitoring is free. No card required.

What to do

Action · 2 steps
01By 2026-12-01: Billing team and providers should review the revised list of proven indications for TARE/SIRT with yttrium-90 microspheres for Tennessee Community Plan Medicaid members aged 19 and older, and confirm that the diagnosis and documentation supporting any scheduled TARE/SIRT case match one of the listed indications (including the updated uveal melanoma wording) before scheduling or billing; obtain authorization where required and update charge entry and encounter documentation so claims reflect the supported diagnosis.
02Front desk staff should be told that TARE/SIRT for indications outside the listed set is considered unproven and not medically necessary under this policy, which may result in claim denial.

Original notice

Transarterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT) for the Treatment of Malignant Cancers of the Liver (for Tennessee Only)
uhcprovider.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account